Robert Forrester, A Serial Entrepreneur, Has Joined The Board Of Directors Of Affyimmune Therapeutics

Mr. Forrester is an EQRx co-founder. He also serves on the boards of IDRx, Brixton Biosciences, and EyeCool Therapeutics.

Fremont, CA: AffyImmune is expanding the anti-cancer effectiveness of CAR T cell treatment to solid tumors, achieving cancer immunotherapy's potential. The Tune & Track platform from AffyImmune fine-tunes CAR T cell affinity to decrease toxicity and boost CAR T cell lifetime while providing in vivo monitoring via unique tracking technology. The firm was launched in 2016 and planned to enroll patients in its Phase 1 study for advanced thyroid cancer in 2020.

"Robert brings a wealth of experience to AffyImmune, and our management team will certainly benefit from lessons learned in his time as an executive and a director throughout the biotech sector. He has rapidly become a trusted partner to our management team, and we look forward to working with him in the years to come," said AffyImmune President Matt Britz.

AffyImmune Therapeutics, Inc. has appointed serial biotech entrepreneur Robert Forrester to its Board of Directors. Mr. Forrester has over two decades of biotech expertise as a chief financial officer, chief operating officer, chief executive officer, and board member. In addition, he has decades of corporate leadership expertise and a proven track record of transitioning firms from the early stages to the growth stage.

"It gives me great pleasure to welcome Robert to AffyImmune's Board of Directors to help steer and govern the company as it scales up its clinical development from advanced thyroid cancers to additional indications. Robert's management experience, strategic mindset, industry connectivity and strong interest in AffyImmune will make him a valuable addition. The Board and team are committed to bringing true patient benefits to those who suffer from solid tumors by using our proprietary Tune & Track CAR T technology," said Simone Song, Chair of AffyImmune's Board of Directors, the founding partner of ORI Capital and ORI Healthcare Funds. "As AffyImmune continues its growth, ORI Capital will continue to incubate, support, and add value, particularly through the attraction and development of top-tier talent."

Mr. Forrester is an EQRx co-founder. He also serves on the boards of IDRx, Brixton Biosciences, and EyeCool Therapeutics. He is also a director of Pillar Biosciences and Deciduous Therapeutics. In the United Kingdom, he earned law degrees from the University of Bristol and the University of Law Guildford.